Moderna Shares Double After Cancer Treatment Update

Moderna’s shares rose about 100% in a single trading session on Nasdaq after the company reported early clinical results for an investigational mRNA-based cancer therapy. Trading volume increased sharply compared with recent sessions. The stock trades under the ticker MRNA.

Moderna, based in Massachusetts and best known for its COVID-19 vaccine, provided the update to investors and the public, describing data it said showed encouraging signs of effectiveness in an oncology program.

The company said the therapy remains investigational and must complete further clinical trials and regulatory review before it can be prescribed. Moderna noted that larger, later-stage trials and more detailed safety and efficacy data will be required for regulators to assess the treatment.

Moderna has been developing treatments that use mRNA to instruct cells to produce proteins intended to train the immune system or correct disease processes. Since 2020, the company has expanded its pipeline into oncology, rare diseases and other infectious diseases.

Analysts and investors responded to the announcement by buying shares, contributing to the rapid price increase and higher trading volume. Large intraday swings are common in biotech when companies release early clinical data.

Investors will watch for follow-up details from Moderna, including full data releases, peer-reviewed publications, planned designs for larger trials and regulatory timelines.

Moderna was founded in 2010 and became widely known after its mRNA COVID-19 vaccine received emergency use authorizations in 2020.